Guang-Cong Zhang
Overview
Explore the profile of Guang-Cong Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang G, Song K, Wang X, He Z, Du J, Sun J, et al.
Colloids Surf B Biointerfaces
. 2024 Oct;
245:114279.
PMID: 39368423
Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), has limited clinical application due to severe side effects and drug resistance. To overcome these challenges, we developed a bismuth-based...
2.
Liu Z, Lin X, Guo H, Shi X, Zhang D, Sun J, et al.
Int J Biol Sci
. 2024 May;
20(7):2763-2778.
PMID: 38725845
Dysregulation of the aldehyde dehydrogenase (ALDH) family has been implicated in various pathological conditions, including cancer. However, a systematic evaluation of ALDH alterations and their therapeutic relevance in hepatocellular carcinoma...
3.
Wang F, Xu W, Zhang W, Xu R, Sun J, Zhang G, et al.
Hepatol Int
. 2023 Nov;
18(2):636-650.
PMID: 37982952
Background: Aberrant iron metabolism is commonly observed in multiple tumor types, including hepatocellular carcinoma (HCC). However, as the key regulator of iron metabolism involved in iron absorption, the role of...
4.
Liu Z, Chen G, Wang X, Xu R, Wang F, Qi Z, et al.
Adv Healthc Mater
. 2023 Jun;
12(27):e2301133.
PMID: 37311013
Ferroptosis is identified as a novel type of cell death with distinct properties involved in physical conditions and various diseases, including cancers. It is considered that ferroptosis provides a promising...
5.
Zhang G, Yu X, Guo H, Sun J, Liu Z, Zhu J, et al.
Cancer Res
. 2023 Feb;
83(4):521-537.
PMID: 36723974
Significance: Upregulation of pre-mRNA processing factor 19 (PRP19) contributes to esophageal squamous cell carcinoma progression by reprogramming SREBF1-dependent fatty acid metabolism, identifying PRP19 as a potential prognostic biomarker and therapeutic...
6.
Xu R, Wang F, Sun J, Abuduwaili W, Zhang G, Liu Z, et al.
J Transl Med
. 2022 Dec;
20(1):579.
PMID: 36494846
Primary liver cancer (PLC) is a common gastrointestinal malignancy worldwide. While hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two major pathologic types of PLC, combined HCC and ICC (cHCC-ICC)...
7.
Huang A, Du J, Liu Z, Zhang G, Abuduwaili W, Yan J, et al.
Nanomaterials (Basel)
. 2022 Sep;
12(18).
PMID: 36144982
Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment,...
8.
Liu Z, Zhang D, Lin X, Sun J, Abuduwaili W, Zhang G, et al.
Front Pharmacol
. 2022 Sep;
13:952482.
PMID: 36071851
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs...
9.
Niu H, Zhang L, Wang B, Zhang G, Liu J, Wu Z, et al.
J Clin Transl Hepatol
. 2022 Sep;
10(4):680-691.
PMID: 36062271
Background And Aims: Radiation-induced liver fibrosis (RILF), delayed damage to the liver (post-irradiation) remains a major challenge for the radiotherapy of liver malignancies. This study investigated the potential function and...
10.
Abuduwaili W, Wang X, Huang A, Sun J, Xu R, Zhang G, et al.
ACS Appl Mater Interfaces
. 2022 Aug;
14(33):37356-37368.
PMID: 35951459
Although sorafenib, a multi-kinase inhibitor, has provided noteworthy benefits in patients with hepatocellular carcinoma (HCC), the inevitable side effects, narrow therapeutic window, and low bioavailability seriously affect its clinical application....